PYC Therapeutics Limited Financials

Market Capitalization A$657.1 Million as of July 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE	-9.20
Price to Sales TTM	A$19.37
Price to Book MRQ	A$11.50
Enterprise to Revenue	15.03
Enterprise to EBITDA	-14.91

Financial Reports as of Jun. 30, 2023

Financials

Fiscal Year Ends	2023-06-30
Most Recent Quarter	2023-06-30
Profit Margin	-101.90%
Operating Margin	-173.29%
Return on Assets TTM	-38.38%
Return on Equity TTM	-80.66%

Income Statement

Revenue TTM	A$21,241,436
Revenue per Share TTM	A$0.01
Quarterly Revenue Growth	156.50%
Gross Profit TTM	A$0
EBITDA	A$-21,413,048
Net Income to Common TTM	A$-21,645,216
Diluted EPS TTM	A$-0.01
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	A$25,413,572
Total Cash per Share MRQ	A$0.01
Total Debt MRQ	A$
Total Debt to Equity MRQ	1.77
Current Ratio MRQ	3.99
Book Value per Share MRQ	A$0.01

Cash Flow

Operating Cash Flow TTM	A$-19,381,880
Levered Free Cash Flow TTM	A$-12,897,028

PYC Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	4,471,980,032
Float Shares	1,512,632,420
Avg 10 Volume	2,062,397
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	60.40%
% Held by Institutions	0.00%

Stock Price Summary

Beta	0.64
Fifty Two Week Low	A$0.05
Fifty Two Week High	A$0.12
Fifty Two Week Change	39.05%
Day 50 MA	A$0.09
Day 200 MA	A$0.08

Dividends and Splits

Forward Annual Dividend Rate	A$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	A$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date